Please login to the form below

Not currently logged in

GSK pays $85m upfront for Surface Oncology’s lead cancer drug

British pharma company adds preclinical antibody to its pipeline

GlaxoSmithKline (GSK) has added a preclinical oncology asset to its pipeline after paying $85m upfront for Surface Oncology’s lead asset.

The preclinical programme includes SRF813, a fully human IgG1 antibody targeting PVRIG – an inhibitory protein expressed on natural killer cells (NK cells) and T cells.

SRF813 binds to a distinct epitope on PVRIG and blocks the interaction between this protein and CD112, its binding partner that is over-expressed on tumour cells.

According to Surface, in preclinical studies SRF813 was found to promote the activation of both NK cells and T cells, which it says reflects a potential to produce strong anti-tumour responses and promote immunological memory.

Currently, SRF813 is in investigational new drug (IND)-enabling studies, with an IND filing planned for 2021.

As well as the upfront payment, Surface will be eligible to receive up to an additional $730m in future milestone payments, as well as tiered royalties on global net sales.

“GSK’s R&D approach focuses on the science of the immune system and I am excited to add a natural killer cell approach, such as SRF813, as it complements our existing programmes focused on T cell/adaptive immunity,” said Axel Hoos, senior vice president and head of oncology R&D at GSK.

“We’re making great progress to build an exciting pipeline of new oncology therapies with transformational potential for patients. I strongly believe that we are uniquely positioned to maximise the potential of SRF813 for patients, both as monotherapy and in potential combinations with our investigational anti-CD96 and anti-PD1 assets,” he added.

Aside from SRF813, Surface’s wholly-owned lead programmes includes a CD39-targeting asset – SRF617 – and an IL-27 inhibitor – SRF388. It also has a preclinical programme developing a CCR8-targeting asset – SRF114 – focused on depleting regulatory T cells.

“The economics of the (GSK) transaction position us well to continue to drive the development of our wholly-owned clinical programmes, SRF617 and SRF388, while also advancing SRF114, our CCR8 targeted programme,” said Jeff Goater, chief executive officer of Surface.

The biotech also has a clinical-stage collaboration programme with Novartis which includes a CD73-targeting asset – NZV930.

Novartis signed an agreement with Surface in 2016 to license four preclinical programmes from Surface’s portfolio.

The company is also collaborating with Merck & Co (MSD) on a clinical trial evaluating the safety and efficacy of SRF617 in combination with Merck’s blockbuster PD-1 inhibitor Keytruda (pembrolizumab).

Article by
Lucy Parsons

18th December 2020

From: Research



COVID-19 Updates and Daily News

Featured jobs


Add my company

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >300 healthcare communications professionals,...

Latest intelligence

Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
Rare thoughts & outcomes - navigating pathways to better outcomes in rare
How to pick the perfect training program for your healthcare professionals
You know your team needs training. But not all training providers and programs are created equal. Last week, we shared the benefits of working with specialist learning and development (L&D)...